Clinical Trial Update: Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors [EARLY_Phase 1]

View source ↗

Summary

Completed EARLY Phase 1 clinical trial evaluating memantine to reduce cognitive impairment after radiation therapy in pediatric central nervous system tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Central Nervous System Neoplasms

Drugs mentioned

• Namenda (memantine)

Snippet

Sponsor: Mayo Clinic | Conditions: Malignant Central Nervous System Neoplasm, Primary Central Nervous System Neoplasm | EARLY_Phase 1 | Status: COMPLETED